Bevacizumab for the Treatment of Corneal Neovascularization

NCT00992849 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Corneal Neovascularization

Interventions

DRUG: Bevacizumab

Sponsor

Chang Gung Memorial Hospital